NeoGenomics Radar Assay; Neo Comprehensive-Solid Tumor and Neo Comprehensive-Myeloid Disorders
NeoGenomics has commercially launched its Radar liquid biopsy test for minimal residual disease (MRD) for clinical use. The assay has been available for use in clinical research studies and pharmaceutical collaborations for more than a year, but it will now be available to US clinicians treating breast, colorectal, lung, and head and neck cancer patients. The laboratory-developed test tracks up to 48 tumor-specific variants in cell-free DNA in a patient's blood plasma and is intended to detect MRD and recurrence after curative intent or definitive treatment.
NeoGenomics this week also announced the commercial availability of new sequencing-based comprehensive genomic profile tests Neo Comprehensive-Solid Tumor and Neo Comprehensive-Myeloid Disorders.
Neo Comprehensive-Solid Tumor is the company's largest solid tumor, pan-cancer assay available to date. It detects genomic alterations that are most relevant in diagnosis, therapy selection, prognosis, and clinical trials, the company said. The panel assays 517 genes using DNA and RNA sequencing, and includes microsatellite instability and tumor mutational burden.
Neo Comprehensive-Myeloid Disorders enhances the company's previous myeloid panel, making it the largest DNA and RNA sequencing-based myeloid panel on the market, the company said. It analyzes 164 genes and includes single-nucleotide variants, copy number variants, insertions and deletions, and fusions.
NeoGenomics also said it is introducing two software resources to complement its testing menu: NeoAccess, a test requisitioning tool with clinical decision support; and NeoSeek software that enables clinicals to mine their previous testing data to identify patients who may be biomarker-eligible for a new therapy or clinical trial.